PAK4 and neoplasm: These results suggest that PAK4 inhibition in OSCC tumour-bearing mice abrogates the expression of PD-L1 on tumour cells and increases the expression of MHC molecules and lymphocyte co-stimulatory molecules on DCs in tumours, enhancing the anti-tumour immune response.